Strata Critical Medical (SRTA) Cost of Revenue (2021 - 2026)

Strata Critical Medical (SRTA) has 6 years of Cost of Revenue data on file, last reported at $53.3 million in Q1 2026.

• Quarterly Cost of Revenue rose 84.35% year-over-year to $53.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $247.5 million (up 9.88% YoY) and the FY2025 annual result came in at $156.0 million, up 33.09% from the prior year.
• Cost of Revenue retreated to $53.3 million in Q1 2026 per SRTA's latest filing, from $154.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $175.0 million in Q4 2023 and bottomed at $1.6 million in Q2 2025.
• The 5-year median for Cost of Revenue is $38.1 million (2023), against an average of $55.1 million.
• The widest annual swing landed in 2023, when Cost of Revenue soared 2017.06%; it then plunged 96.83% in 2025.
• Tracing SRTA's Cost of Revenue over 5 years: stood at $30.5 million in 2022, then surged by 473.47% to $175.0 million in 2023, then slumped by 33.61% to $116.2 million in 2024, then surged by 33.32% to $154.9 million in 2025, then slumped by 65.62% to $53.3 million in 2026.
• Per Business Quant, the three latest SRTA Cost of Revenue figures stand at $53.3 million (Q1 2026), $154.9 million (Q4 2025), and $37.7 million (Q3 2025).

Peer Comparison